EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase IV)Open Access

Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study

Shun Ishibashi, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Mao Watanabe, Michiko Nakanishi, Yuichi Makinose, Hideki Suganami, Yuji Kurihara, Shizuya Yamashita

Journal of Atherosclerosis and Thrombosis · 01.02.2025 · 32 (2) · 210-225

DOI: 10.5551/jat.64887 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Atherosclerosis and Thrombosis, erschienen am 01.02.2025. Verfasst von Shun Ishibashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Jichi Medical University. Hauptthemen laut MEDLINE: Benzoxazoles, Butyrates, Dyslipidemias, Renal Insufficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoxazolesButyratesDyslipidemiasRenal InsufficiencyHumansMaleFemaleMiddle AgedDouble-Blind MethodAgedGlomerular Filtration RateAdultFollow-Up Studies

Stichwörter der Autor:innen

DyslipidemiaPemafibratePharmacokineticsSevere renal impairmentTriglycerides

Substanzen

(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidBenzoxazolesButyrates

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Jichi Medical University.
  • Ishibashi Diabetes and Endocrine Clinic.
  • National Center for Geriatrics and Gerontology.
  • Chiba University.
  • Kikuchi Medical Association Hospital.
  • Research Center for Health and Sports Sciences, Kumamoto Health Science University.

Zitieren

APA

Ishibashi, S., Arai, H., Yokote, K., Araki, E., Watanabe, M., Nakanishi, M., Makinose, Y., Suganami, H., Kurihara, Y., & Yamashita, S. (2025). Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study. Journal of Atherosclerosis and Thrombosis, 32(2), 210-225. https://doi.org/10.5551/jat.64887

Vancouver

Ishibashi S, Arai H, Yokote K, Araki E, Watanabe M, Nakanishi M, et al. Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study. Journal of Atherosclerosis and Thrombosis. 2025;32(2):210-225. doi:10.5551/jat.64887

BibTeX
@article{Ishibashi2025,
  author = {Ishibashi, Shun and Arai, Hidenori and Yokote, Koutaro and Araki, Eiichi and Watanabe, Mao and Nakanishi, Michiko and Makinose, Yuichi and Suganami, Hideki and Kurihara, Yuji and Yamashita, Shizuya},
  title = {Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2025},
  volume = {32},
  number = {2},
  pages = {210--225},
  doi = {10.5551/jat.64887}
}
Kostenlos starten →